Jun 14, 2022 / 10:20PM GMT
Madhu Sudhan Kumar - Goldman Sachs Group, Inc., Research Division - Research Analyst
Hey, everyone. So thanks for joining us this afternoon. We're so excited to have the team from Syndax Pharmaceuticals here today to tell us kind of an update on where things are, where things are headed. So I'll let Mike Metzger give us some introductory remarks, then we'll just dive right in.
Michael A. Metzger - Syndax Pharmaceuticals, Inc. - CEO & Director
Great. Well, thanks, Madhu. Thanks to the Goldman team for inviting us to the conference. It's a great venue. Great to see people in person. So I appreciate that. So most of you are familiar with Syndax, but just a reminder, we're a targeted oncology company, developing 2 agents in our pipeline, both are in registration trials for relapsed/refractory disease. Importantly, we have the opportunity to bring data -- pivotal data in 2023, the first half of 2023. So that's in the next 12 months as well as have regulatory filings, 2 regulatory filings in 2023. Both assets are poised to be first to market and best in class and
Syndax Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 15, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers